TBPH - テラバンス・バイオファ―マ (Theravance Biopharma Inc.)

TBPHのニュース

   Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates  2020/07/31 19:56:58 Benzinga
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the total number of NME approvals for the year to 29. Here are the key PDUFA dates scheduled for August. GSK Seeks To Expand Use Of Triple Combo Drug To Asthma Company: GlaxoSmithKline plc (NYSE: GSK ) Type of Application: sNDA Candidate: Trelegy Elypta Indication: asthma Date: Aug. 2 (estimated based on the 10-review period from the regulatory application filing date of Oct. 2) Trelegy Elypta is a single inhaled triple therapy consisting of fluticasone furoate/umeclidinium/vilanterol) and has already been approved for chronic obstructive pulmonary disease.
   Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors  2020/07/02 10:00:00 PR Newswire
DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the…
   Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?  2020/06/05 15:31:46 Zacks Investment Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know  2020/04/29 16:33:58 Zacks Investment Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know  2020/04/28 16:33:45 Zacks Investment Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates  2020/07/31 19:56:58 Benzinga
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the total number of NME approvals for the year to 29. Here are the key PDUFA dates scheduled for August. GSK Seeks To Expand Use Of Triple Combo Drug To Asthma Company: GlaxoSmithKline plc (NYSE: GSK ) Type of Application: sNDA Candidate: Trelegy Elypta Indication: asthma Date: Aug. 2 (estimated based on the 10-review period from the regulatory application filing date of Oct. 2) Trelegy Elypta is a single inhaled triple therapy consisting of fluticasone furoate/umeclidinium/vilanterol) and has already been approved for chronic obstructive pulmonary disease.
   Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors  2020/07/02 10:00:00 PR Newswire
DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the…
   Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?  2020/06/05 15:31:46 Zacks Investment Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know  2020/04/29 16:33:58 Zacks Investment Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know  2020/04/28 16:33:45 Zacks Investment Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference  2020/01/07 21:48:00 PR Newswire
DUBLIN, Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38th Annual J.P. Morgan…
   Theravance Biopharma : , Pfizer in License Agreement | MarketScreener  2019/12/23 13:53:01 MarketScreener
By Michael Dabaie Theravance Biopharma and Pfizer said they entered into a global license agreement for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase,… | December 23, 2019
   Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue?  2019/12/05 16:31:10 Zacks Investment Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases  2019/12/03 12:50:00 PR Newswire
DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK)…
   Theravance Biopharma : Summary ToggleTheravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference | MarketScreener  2019/11/06 22:10:23 MarketScreener
DUBLIN, Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 - Theravance Biopharma, Inc. announced today that management will participate in a corporate presentation at the 28th Annual… | November 6, 2019

calendar